Detail akcie Zai Lab Unsp ADR online

Business Summary: Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Zai Lab Ltd - ADR revenues increased 15% to $332.6M. Net loss decreased 29% to $125.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Personnel compensation and related costs decrease of 31% to $92.2M (expense), Labor & Related Expenses in R&D decrease of 39% to $50.8M (expense).